>>>The recent run to .005 is a classic example, proving the point that escalating prices are not sustainable with this structure.<<<
THAT is NOT the reason the stock price fell back fell to triple zeros. The rise to .005 was quickly after FDA cleared for the TWO uses. ONLY TWO uses. REPEAT, ONLY TWO uses. And neither was for the most prevalent physiological human pain: BACK PAIN. That, anyone with common sense KNOWS, is what the company and ALL stockholders were waiting for. Big disappointment to investors as it all sank in. The thought that they (company) would have to go back AGAIN and trial and prove to the FDA with more DATA, and knowing the TIME that it would take to do so, scared many out of the stock, thus selling and on the sidelines watching again. IMO they WILL be back once this all gets straightened out, if it ever does, and they DO get that USA FULL CLEARANCE for ALL muscle and joint pain.
In the meantime, another opportunity for us to add in these trips.
Market Data 
Markets 
